Could chemo before surgery boost survival in pancreatic cancer?
NCT ID NCT02959879
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving chemotherapy before surgery (neoadjuvant chemo) helps people with resectable pancreatic cancer live longer. 153 patients were randomly assigned to either standard surgery followed by chemo, or one of two chemo regimens (FOLFOX or FOLFIRINOX) before surgery. The goal was to see if the neoadjuvant approach improves survival and reduces cancer recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy (FOLFOX or FOLFIRINOX)
- What this could lead to
- If it works, giving chemotherapy before surgery could help more patients live longer and reduce the chance of cancer coming back.
- What could go wrong
- This is a phase 2 trial with only 153 participants, so results are not definitive. Chemotherapy before surgery may not improve outcomes and can cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE PANCREATIC DUCT ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rouen University Hospital
Rouen, France